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Background: To construct a recombinant adenovirus containing CDglyTK double suicide genes and evaluate the
killing effect of the double suicide genes driven by kinase domain insert containing receptor (KDR) promoter on
human umbilical vein endothelial cells.
Methods: Human KDR promoter, Escherichia coli (E. coli) cytosine deaminase (CD) gene and the herpes simplex virus-
thymidine kinase (TK) gene were cloned using polymerase chain reaction (PCR). Plasmid pKDR-CDglyTK was constructed
with the KDR promoter and CDglyTK genes. A recombinant adenoviral plasmid AdKDR-CDglyTK was then constructed
and transfected into 293 packaging cells to grow and harvest adenoviruses. KDR-expressing human umbilical vein
endothelial cells (ECV304) and KDR-negative liver cancer cell line (HepG2) were infected with the recombinant
adenoviruses at different multiplicity of infection (MOI). The infection rate was measured by green fluorescent protein
(GFP) expression. The infected cells were cultured in culture media containing different concentrations of prodrugs
ganciclovir (GCV) and/or 5-fluorocytosine (5-FC). The killing effects were measured using two different methods, i.e.
annexin V-FITC staining and terminal transferase-mediated dUTP nick end-labeling (TUNEL) staining.
Results: Recombinant adenoviruses AdKDR-CDglyTK were successfully constructed and they infected ECV304 and
HepG2 cells efficiently. The infection rate was dependent on MOI of recombinant adenoviruses. ECV304 cells
infected with AdKDR-CDglyTK were highly sensitive to GCV and 5-FC. The cell survival rate was dependent on both
the concentration of the prodrugs and the MOI of recombinant adenoviruses. In contrast, there were no killing
effects in the HepG2 cells. The combination of two prodrugs was much more effective in killing ECV304 cells than
GCV or 5-FC alone. The growth of transgenic ECV304 cells was suppressed in the presence of prodrugs.
Conclusion: AdKDR-CDglyTK/double prodrog system may be a useful method for suppressing tumor angiogenesis.
Background
Anti-angiogenic therapy has been proved to be a
rational approach in the treatment of solid tumors [1].
The advantages of anti-angiogenic approach include
new vessels targeting, the lack of mutations in the
endothelial cells, and the amplification effect on tumor
killing [2]. But targeting endothelial cells by gene ther-
apy was hampered by the inefficiency of the vascular-
specific promoters. In the present work, we used a mod-
ified kinase domain insert containing receptor (KDR)
promoter to direct gene expression in endothelial cells.
KDR gene is strictly expressed only in vascular endothe-
lial cells. The activity of the KDR promoter in
endothelial cells is similar to that of the potent SV40
promoter/enhancer and it is specific to endothelial cells,
i.e., the activity of KDR promoter in other cell types is
markedly diminished [3].
A prerequisite for effective anti-vascular gene therapy is
the use of a potent “killer” gene. A suicide gene is a gene
encoding an enzyme that converts nontoxic prodrugs
into toxic forms [4]. Studies have indicated that apart
from direct killing effects of a suicide gene, which kills its
host cells only, its “bystander effects” could induce death
to the nearby cells. These characteristics allow a thera-
peutic application of suicide genes to tumors. TK and
CD gene are the most widely studied suicide genes [4,5].
But both of them have their drawbacks. Therefore, the
fusion gene TKglyCD is proposed to be a new suicide
gene with better therapeutic effects [6].
* Correspondence: cheguowei@yahoo.com.cn
2Department of Thoracic Surgery, West China Hospital, Sichuan University,
Chengdu 610041, PR China
Full list of author information is available at the end of the article
Jia et al. Virology Journal 2011, 8:74
http://www.virologyj.com/content/8/1/74
© 2011 Jia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.In this study, we proposed that the use of KDR pro-
moter in combination with double suicide genes that
were specifically activated in the tumor’sv a s c u l a r
endothelial cells would provide us with high levels of
tumor specificity. The aim of the present work was to
generate a replication-deficient adenovirus vector,
expressing TK and CD under the control of KDR pro-
moter, as an anti-angiogenesis tool in cancer therapy.
Materials and methods
Cell culture
Human umbilical vein endothelial cells ECV304 and
human hepatoma cells HepG2w e r ec u l t u r e di nR P M I
1640 medium containing 10% fetal calf serum. Human
embryonic kidney 293 cells were cultured in DMEM
containing 10% fetal calf serum.
Construction of the recombinant plasmids
Plasmids pGL3-Basic and pGL3-Control contained the
firefly luciferase gene (Promega). pGL3-Basic had no
promoter, whereas pGL3-Control was driven by the
SV40 promoter and enhancer. The plasmid pSV-bgal
(Promega) contained the b-galactosidases gene driven by
the SV40 promoter and enhancer. Reporter construct
containing fragment of the human KDR promoter
region from -125 to +227 (366 bp) was inserted into
pGL3-Basic and named pGL3-KDR. KDR promoter
region was amplified from the genomic DNA of
ECV304 cells by PCR. The primers were: forward 5’-
GCT CGA GTT GTT GCT CTG GGA TGT TCT-3’
(containing NruIs i t e ) ,a n dr e v e r s e5 ’-G A AG C TT G T
GCC GGT AGG AGA GGA TAT -3’ (containing Hin-
dIII site).
AdKDR-CDglyTK plasmid was created as the follow-
ing: first, CD and TK genes were amplified from the E.
coli JM109 DNA and the plasmid pcDNA3-TK, respec-
tively. Then, these two DNA fragments were inserted
together into pcDNA3 vector to generate pcDNA3-
CDglyTK. After digesting KDR fragment and pcDNA3-
CDglyTK with Nrul and HindIII, these two DNA frag-
ments were ligated together to form pcDNA3-KDR-
CDglyTK. Finally, KDR-CDglyTK DNA fragment from
pcDNA3-KDR-CDglyTK plasmid was inserted into pAd-
track vector to generate pAdtrack-KDR-CDglyTK plas-
mid. The pAdtrack-KDR-CDglyTK and pAdEasey-1
plasmids were co-transfacted into E.coli BJ5183 using
the electroporation method. Thirty two positive colonies
were screened and analyzed by restriction enzyme diges-
tion. The PCR primers were: CD (1.3 kb) forward 5’-
AAG CTT AGG CTA GCA ATG TCG AAT AAC
GCT -3’, and reverse 5’- GGA TCC TCC ACG TTT
GTA ATC GAT GGC TTC -3’; TK (1.1 kb) forward 5’-
GGA TCC GGC GGG GGC GGT GGA GGA GGG
GGT ATG GCT TCG TAC -3’, and reverse 5’-T C T
AGA TTA GTT AGC CTC CCC CAT CTC -3’; b-actin
(500 bp) forward 5’G A CT A CC T CA T GA A GA T C3 ’,
and reverse 5’GAT CCA CAT CTG CTG GAA 3’.A l l
constructs were sequenced from the 5’ and 3’ ends to
confirm orientation and sequence.
Transfections
Two cell types were transfected using Lipofectamine
2000 (Roche, USA) according to manufacturer’sp r o t o -
col. For luciferase assay, 5 × 10
5 cells/35-mm plate were
seeded and incubated at 37°C in 5% CO2 overnight.
Next day, 2 μg of reporter plasmids DNA and 0.5 μgo f
pSV-bgal were mixed with the Lipofectamine 2000
reagent and added onto the cell monolayer. After incu-
bation for an additional 48 hours, luciferase activity was
measured in duplicate for all samples using a TD-20/20
Luminometer (Turmer Designs, Sunnyvale, CA) and the
Promega luciferase assay system [7]. Beta-galactosidase
activity was assayed as described previously. The pGL3-
Control was used as positive control and its luciferase
activity was considered 100%. Viral DNAs were trans-
fected in 293 cells to package viruses. Propagations of
the recombinant viruses could be visualized by GFP
expression under a fluorescence microscope. The viral
supernatant was purified in CsCl gradient with ultracen-
trifuge and the titration of AdKDR-CDglyTK viruses
was measured using plaque formation assay. The recom-
binant viruses were stored at -80°C for use.
RNA isolation and Reverse Transcription
Total RNA from cells was prepared using Trizol reagent
according to the manufacturer’sp r o t o c o l( I n v i t r o g e n ,
Carlsbad, CA). Two micrograms total RNA was reverse
transcribed using the High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s protocol with a minor modifica-
tion: addition of RNase inhibitor (Applied Biosystems,
Foster City, CA, USA) at a final concentration of 1 U/μl.
The complete reaction mixes were incubated at 25°C for
10 min and 37°C for 120 min.
Western blot analysis
Cell extracts (10 ng total protein/lane) were separated by
standard sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis under reducing conditions and transferred to
polyvinylidene difluoride membranes using a semidry
blotting apparatus. After blocking in 5% nonfat dry milk
in Tris-buffered saline (TBS) containing 0.1% Tween 20,
the membranes were incubated with primary antibodies
(dilution 1:100) for 1 h. The primary antibodies were rab-
bit polyclonal antibodies against TK and CD, kindly pro-
vided by William Summers, Yale University. Following
incubation with primary antibodies and three washes, the
membranes were incubated with peroxidase-conjugated
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1 h. After three washes, the specific protein bands were
visualized with chemiluminescence reagent using the
Western blot chemiluminescence system.
In vitro cytotoxicity assays
Briefly, cells were infected in suspension for 1 h at dif-
ferent MOIs and dispensed into 96-well, flat-bottom
microtiter plates at a concentration of 1 × 10
4 cells in
100 μl per well. The cells were incubated with or with-
out GCV (5 μg / m l ;R o c h e ,U S A )a n d / o r5 - F C( 1 0 0μg/
ml; Roche, USA) at 37°C in a 5% CO2 Incubator. After
incubation for 72 h, cell viability was determined by
standard MTT assay using Cell Titer 96
® Aqueous One
Solution Reagent Kit (Promega). For bystander effect
assay, the infected cells and uninfected cells were mixed
in a 1:1 ratio and seeded into 96-well plates with 1 ×
10
4 cells in 100 μl per well. Cells were treated and ana-
lyzed as described above. The percentage of viable cells
was calculated as % viability = (number of viable cells
counted/total number of cells counted) × 100%.
Flow cytometry analysis of apoptotic cells
To determine the effect of recombinant viruses on
apoptosis, 1 × 10
5 of infected or uninfected cells/well
were seeded into 6-well plates. The cells were incubated
i nt h ep r e s e n c eo ra b s e n c eo fG C V( 5μg/ml) and/or 5-
FC (100 μg/ml) at 37°C in a 5% CO2 incubator. After
incubation for 72 h, cells were stained using Annexin V-
FITC Apoptosis Analysis Kit (PharMingen) and sub-
jected to a FACS Calibur flow cytometry (Becton Dick-
inson, Mountain View, CA) to sort out the Annexin V-
FITC stained apoptotic cells. Data were analyzed by
CELLQuest software (Becton Dickinson, San Jose, CA).
The apoptotic index (AI) was calculated as the percen-
tage of apoptotic cells in the treated cell population




5 of cells/well were seeded into 6-well plates.
After 72 h treatment with GCV (5 μg/ml) and/or 5-FC
(100 μg/ml), cells were trypsinized and fixed on slides
followed by staining using In Situ Cell Death Detection
Kit (Roche). Apoptotic cells with characteristic nuclear
fragmentation (staining green) were counted in 10 ran-
domly chosen fields. The apoptotic index (AI) was cal-
culated by subtracting the percentage of apoptotic cells
in the untreated control cell population from percentage
of apoptotic cells in the treated cell population.
Statistical analysis
For flow cytometry analysis, each experiment was dupli-
cated and repeated three times. For cell viability assay,
each experiment was analyzed in triplicate and repeated
at least three times. Data were analyzed using One-Way
ANOVA and LSD test. A p-value < 0.05 was considered
statistically significant.
Results
High levels of CD and TK expression induced by the KDR
promoter was found in ECV304 endothelial cells, but not
in hepatoma HepG2 cells
To determine whether KDR promoter confers endothelial
cell-specific expression in cultured cells, we constructed a
pGL3-KDR luciferase reporter plasmid. These plasmids
were co-transfected into ECV304 endothelial cells and
HepG2 cells with pSV-bgal to correct for differences in
transfection efficiency. The luciferase activity was normal-
ized to that of the pGL3-Control vector driven by the
SV40 promoter/enhancer. We found that the pGL3-KDR
luciferase activity was about 92% of that of pGL3-Control
vector in ECV endothelial cells (p < 0.05). In contrast, the
pGL3-KDR luciferase activity was barely detectable in the
HepG2 cells, though the pGL3-Control vector showed
high luciferase activity in this cell line (Figure 1A).
Recombinant viruses
The pAdtract-KDR-CDglyTK and pAdEasey-1 plasmids
were co-transfected into 293 cells to package viruses.
Most of 293 cells expressed GFP protein after incuba-
tion for 3 days, indicating high transfection efficiency.
The titer of purified recombinant viruses was measured
to be 3 × 10
12 pfu/L by plaque formation assay. In addi-
tion, we confirmed the presence of the CDglyTK fusion
gene and KDR promoter from the boiled recombinant
viruses using PCR analysis (Figure 1B).
Expression of CDglyTK fusion gene
Human umbilical vein endothelial cells (ECV304) and
human hepatoma cells (HepG2) were infected with dif-
ferent MOIs of purified recombinant viruses. MOI of 1
only achieved infection of a minority of cells and MOIs
of 100 and 200 achieved infection of 94% to 100% of the
cells. To identify expression of CDglyTK gene in the
infected cells, RNAs and protein were extracted from
the infected and uninfected cells and analyzed by RT-
PCR and Western blot analysis. The expression of b-
actin gene was used as an internal standard. We found
that the CDglyTK fusion gene was only expressed in the
infected ECV304 cells, but not in the infected HepG2 or
uninfected ECV304 or HepG2 cells (Figure 1C).
Cytotoxicity in vitro
To determine if positive or negative KDR expression
caused cell death by AdKDR-CDglyTK, ECV304 and
HepG2 cells were infected with AdKDR-CDglyTK in the
presence or absence of GCV(5 μg/ml) + 5-FC (100 μg/
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ECV304-KDR-CDglyTK cells but not in ECV304,
HepG2-KDR-CDglyTK, or HepG2 cells. To show if
these effects were MOI dependent, ECV304 cells were
infected with increasing MOI from 0 to 100. AdKDR-
CDglyTK in combination with constant dosage of GCV
+ 5-FC resulted in MOI-dependent cell death, with an
88% cell death rate at a MOI of 100 (p < 0.05) (Figure
2A). In contrast, HepG2 cells did not show significant
cell death (p > 0.05) (Figure 2B).
To determine if the cytotoxicity of the prodrugs was
dose-dependent, ECV304 and HepG2 cells were infected
with AdKDR-CDglyTK at a MOI of 100. The cells were
treated with increasing concentrations of GCV and/or
5-FC for 3 days. We found that KDR-expressing
ECV304 cells were highly sensitive to the prodrugs. The
cell survival rate decreased significantly along with
increasing concentrations of the prodrugs (p < 0.05)
(Figure 3A). The cell survival rate of ECV304/KDRp-
CD-TK cells treated with 5-FC + GCV was significantly
lower than those of the cells treated with 5-FC or GCV
alone (p < 0.01). In contrast, HepG2 cells did not show
any significant decrease in cell survival after similar
treatment (p > 0.05) (Figure 3B).
Bystander effect
When the ECV304-KDRp-CDglyTK cells were mixed
with non-infected ECV304 cells at a 1:1 ratio, the cell
death rate was 51.3 ± 3.4% under 5-FC treatment, 46.6
± 2.3% under GCV treatment, and 74.2 ± 4.9% under 5-
FC + GCV treatment, respectively (Figure 4A). The cell
death rate caused by the two prodrugs was significantly
higher than that caused by either prodrug alone (p <
0.05). Again, HepG2 cells did not show any significant
cell death (p > 0.05, compared to the untreated control
groups) (Figure 4B).
AdKDR-CDglyTK/double prodrugs induced apoptosis
We found that the ECV304-KDR-CDglyTK treated with
two prodrugs had about 26% apoptosis (Figure 5A). The
Figure 1 High level activity of the KDR promoter is specific to endothelial cells. A. The luciferase reporter construct pGL3-KDR was
transfected into ECV304 and HepG2 cells. The transfection efficiency was corrected by cotransfection with pSV-bgal. Results are expressed as a
percentage of pGL3-SV40 Control activity for each cell type. B. The amplification of KDR promoter and CDglyTK fusion gene from recombinant
viruses. 1: l-EclT14I DNA marker; 2: Negative control; 3 and 4: The PCR products of CDglyTK gene and KDR promoter using the recombinant
viruses as the template. C. Expression of recombinant TK and CD protein in the infected and uninfected cells analyzed by Western blotting.
Figure 2 Cytotoxicity is dependent on MOI. ECV304 (A) and HepG2 (B) cells at increasing MOI were exposed in vitro to Ad-KDR-CDglyTK in
the presence or absence of GCV + 5-FC, and the number of viable cells was determined by MTT methods after 6 days treatment.
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cantly higher than that of either prodrug alone (p <
0.05). Again, approximately 6% of apoptotic cells were
found in the HepG2 cells treated or untreated with the
AdKDR-CDglyTK/double prodrugs (p > 0.05) (Figure
5C). Similar results were obtained when the cells were
analyzed with TUNEL assay (Figure B, D).
Discussion
Angiogenesis is crucial for the progression and metastasis
of solid tumor and the vasculature of tumor tissue is dif-
ferent from normal vasculature [8]. Tumor vascular tar-
geting therapy could represent an effective therapeutic
strategy to suppress both primary tumor growth and
tumor metastasis. A major drawback of current
approaches using anti-angiogenesis gene therapy is the
lack of tissue-specific targeting. KDR was critically
involved in the regulation of angiogenesis, both in young
and adult animals [9]. Vascular endothelial cells were
renewed at a low speed in normal conditions and their
KDR expression levels were very low, whereas tumor vas-
cular endothelial cells proliferated quickly and their KDR
expression levels were 500-fold higher than those of the
vascular endothelial cells from normal tissues [10].
Therefore, KDR promoter-driven expression of therapeu-
tic genes in tumor vascular endothelial cells can mark-
edly reduce the side effects of gene therapy through
targeting the vascular endothelial cells of tumors [11].
There are several advantages that anti-angiogenesis
gene therapy may offer: (1) a single vessel supports the
survival of many tumor cells by providing oxygen and
nutrients. Thus, destroying one vessel may result in the
death of many tumor cells [12]; (2) endothelial cells in
the tumor vasculature have a lower mutation rate com-
pared to tumor cells, which means that endothelial cells
will unlikely acquire resistance to the therapeutic drugs
[13]; (3) angiogenesis is infrequent in the adult, which
means that therapies which target endothelial cells in
tumor vasculature may not damage normal endothelial
cells and therefore may have minimal toxicities [13]; (4)
one vascular targeting agent may be effective in many
solid tumor types; and (5) the endothelial cells are easily
accessible by intravenous administration of therapeutic
agents [13].
CD and TK are two competent suicide genes. Previous
investigations that employed either CD or TK aiming at
Figure 3 Cytotoxicity is dependent on concentration of the prodrogs. Sensitivity of ECV304-KDR-CDglyTK, HepG2-KDR-CDglyTK, ECV304 and
HepG2 cells to GCV or 5-FC or both of them.
Figure 4 Bystander effects of 5-FC and/or GCV on ECV304-KDR-CDglyTK/ECV304 and HepG2-KDR-CDglyTK/HepG2 cell death.
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ever, the fusion gene of CD and TK presented an excit-
ing superiority in many studies [14-17]. CDglyTK
encodes a bifunctional enzyme possessing both CD- and
TK-specific activities. Cytotoxicity can be enhanced by
concurrently treating CDglyTK-expressing cells with 5-
FC and GCV, resulting in a synergistic effect. Another
benefit of the fusion gene is its ability to avoid the
acquired drug resistance [18,19].
Adenovirus vectors can be prepared at much higher
titers than retroviral vectors and have a high efficiency
of gene transfer regardless of the proliferative state of
tissues whereas retroviral vectors insert their genes only
into dividing cells. Although the duration of in vivo
gene expression with an adenovirus vector is short, the
level of therapeutic gene expression is much higher,
which is of much importance in suicide gene therapy
because the therapeutic effect of suicide genes is to kill
t h et r a n s g e n i cc e l l sa n dc e lls nearby. A transient and
high level expression would be enough, as once its kill-
ing effect is realized, the gene expression would be inac-
tivated due to the death of the host cells, thus a long
expression duration would be meaningless [20,21].
In our experiment, that the pGL3-KDR luciferase
activity was about 92% of that of pGL3-Control vector
in ECV304 endothelial cells. Recombinant adenoviruses
infected HUVEC cells effectively as 94% cells were
infected and expressed GFP when the cells were infected
with viruses at a MOI of 100. Transgenic cells were
highly sensitive to both 5-FC and GCV, and both pro-
drugs showed a similar toxicity. However, a marked
decrease in cell survival was observed when GCV and 5-
FC were used in combination. But our results did not
show obvious decrease in the survival rate of HUVEC
cells that were infected with recombinant adenoviruses
at different MOI, which suggests that the recombinant
virus itself is not much toxic to HUVEC cells.
One limitation in our study is that we did not evaluate
our system in an in vivo animal study. This in vivo
study is ongoing in which the animals bearing lung can-
cer are treated with different dosages of the recombi-
nant adenovirus, followed by the prodrug treatment.
The goal is to test if our system can inhibit tumor
angiogenesis thus inhibiting tumor growth in vivo. If
this study yields positive results, our next steps will be
to conduct human clinical trials, thus translating our
laboratory study into clinical applications.
Conclusions
Our results showed that the adenovirus AdKDR-
CDglyTK plus double prodrugs suppressed cell growth
and induced apoptosis in ECV304 cells, suggesting that
there is some potential in utilizing this system in anti-
angiogenesis therapy against tumors.
Figure 5 The cells were killed via apoptosis. A and C. The ECV304-KDR-CDglyTK, ECV304, HepG2-KDR-CDglyTK, and HepG2 cells were infected
with Ad-KDR-CDglyTK at a MOI of 100 and treated with GCV (5 μg/ml) and/or 5-FC (100 μg/ml) for 6 days. Apoptosis was analyzed by Annexin
V-FITC staining and flow cytometry analysis. B and D. ECV304 and HepG2 cells infected with Ad-KDR-CDglyTK at a MOI 100 in the presence or
absence of o GCV (5 μg/ml) and/or 5-FC (100 μg/ml). Apoptosis was analyzed by TUNEL assays.
Jia et al. Virology Journal 2011, 8:74
http://www.virologyj.com/content/8/1/74
Page 6 of 7Acknowledgements
The authors would like to thank Dr. JinFeng DING for kindly providing CD
and TK plasmid. This work was supported by the National Natural Science
Foundation of China (No.30872547 to Guowei Che).
Author details
1Department of Geriatrics, West China Hospital, Sichuan University, Chengdu
610041, PR China.
2Department of Thoracic Surgery, West China Hospital,
Sichuan University, Chengdu 610041, PR China.
3The Laboratory of Molecular
Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu
610041, PR China.
Authors’ contributions
JW and GC carried out all the experiments, analyzed results and drafted the
manuscript. LL helped to edit the manuscript. LM participated in analysis of
data and preparation of the manuscript. YW participated in the design of
the study and the critical view of manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 31 December 2010 Accepted: 21 February 2011
Published: 21 February 2011
References
1. Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating
endothelial cell in cancer: towards marker and target identification. Nat
Rev Cancer 2006, 6:835-845.
2. Davidoff AM, Nathwani AC: Antiangiogenic gene therapy for cancer
treatment. Curr Hematol Rep 2004, 3:267-273.
3. Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E: Cloning
and functional analysis of the promoter for KDR/flk-1, a receptor for
vascular endothelial growth factor. J Biol Chem 1995, 270:23111-231118.
4. Boucher PD, Im MM, Freytag SO, Shewach DS: A novel mechanism of
synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double
suicide gene therapy. Cancer Res 2006, 66:3230-3237.
5. Moriuchi S, Wolfe D, Tamura M, Yoshimine T, Miura F, Cohen JB,
Glorioso JC: Double suicide gene therapy using a replication defective
herpes simplex virus vector reveals reciprocal interference in a
malignant glioma model. Gene Ther 2002, 9:584-591.
6. Fogar P, Greco E, Basso D, Navaglia F, Plebani M, Pedrazzoli S: Killer genes
in pancreatic cancer therapy. Cell Mol Biol (Noisy-le-grand) 2005, 51:61-76.
7. Xiuli Huang, Rafal Pawliczak, Xiang-Lan Yao, Patricia Madara, Sura Alsaaty,
James HShelhamera, Mark JCowan: Characterization of the human p11
promoter sequence. Gene 2003, 310:133-142.
8. Gururaj AE, Belakavadi M, Salimath BP: Antiangiogenic effects of butyric
acid involve inhibition of VEGF/KDR gene expression and endothelial
cell proliferation. Mol Cell Biochem 2003, 243:107-112.
9. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S: Regulation of vascular
endothelial growth factor receptor-2 expression in pancreatic cancer
cells by Sp proteins. Biochem Biophys Res Commun 2006, 23(345):292-301.
10. Kung SP, Lee CH, Yang AH, Chi CW, Tseng LM, Wu CW: Expression of c-kit,
Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular
epithelial origin. J Chin Med Assoc 2006, 69:74-79.
11. Kaliberov SA, Kaliberova LN, Buchsbaum DJ: Combined ionizing radiation
and sKDR gene delivery for treatment of prostate carcinomas. Gene Ther
2005, 12(5):407-417.
12. Davidoff AM, Kandel JJ: Antiangiogenic therapy for the treatment of
pediatric solid malignancies. Semin Pediatr Surg 2004, 13:53-60.
13. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ: Targeted measles
virus vector displaying echistatin infects endothelial cells via alpha(v)
beta3 and leads to tumor regression. Cancer Res 2005, 65:5292-5300.
14. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO: Double
suicide gene therapy augments the antitumor activity of a replication-
competent lytic adenovirus through enhanced cytotoxicity and
radiosensitization. Hum Gene Ther 2000, 11:67-76.
15. Guowei CHE, Qinghua ZHOU, Lunxu LIU, Hong BU, Yanping WANG,
wen ZHU, Xiaohe CHEN, xiaojun TANG: Experimental study on the
transcriptional targeting gene therapy of double suicide gene driven by
KDR promoter in lung cancer. Science and Technology Review 2006,
24:28-31.
16. Fischer U, Steffens S, Frank S, Rainov NG, Schulze-Osthoff K, Kramm CM:
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-
fluorocytosine suicide gene therapy-induced cell death in glioma cells.
Oncogene 2005, 24:1231-43.
17. Yang WY, Huang ZH, Lin LJ, Li Z, Yu JL, Song HJ, Qian Y, Che XY: Kinase
domain insert containing receptor promoter controlled suicide gene
system selectively kills human umbilical vein endothelial cells. World J
Gastroenterol 2006, 12:5331-5335.
18. Lumniczky K, Safrany G: Cancer gene therapy: combination with radiation
therapy and the role of bystander cell killing in the anti-tumor effect.
Pathol Oncol Res 2006, 12:118-124.
19. Wu DH, Liu L, Chen LH: Antitumor effects and radiosensitization of
cytosine deaminase and thymidine kinase fusion suicide gene on
colorectal carcinoma cells. World J Gastroenterol 2005, 11:3051-3055.
20. Dharmapuri S, Peruzzi D, Aurisicchio L: Engineered adenovirus serotypes
for overcoming anti-vector immunity. Expert Opin Biol Ther 2009,
9:1279-1287.
21. Zhang H, Xie J, Xie Q, Wilson JM, Gao G: Adenovirus-adeno-associated
virus hybrid for large-scale recombinant adeno-associated virus
production. Hum Gene Ther 2009, 20:922-929.
doi:10.1186/1743-422X-8-74
Cite this article as: Jia et al.: Double suicide genes selectively kill human
umbilical vein endothelial cells. Virology Journal 2011 8:74.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jia et al. Virology Journal 2011, 8:74
http://www.virologyj.com/content/8/1/74
Page 7 of 7